Skip to main content
Signal8
Launch Terminal

VERTEX PHARMACEUTICALS INC / MA (VRTX)

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Vertex Pharmaceuticals Incorporated logo

Vertex Pharmaceuticals Incorporated

NASDAQ:VRTXHealthcare
+3.50%$558.88
AH$554.00-0.87%vs close
Mkt Cap$141.65B
Float253.32M
O/S253.46M
Vol
$ Vol
RVOL
Inst Own94.5%
Earnings
Dilution
Vertex Pharmaceuticals Incorporated logoNASDAQ:VRTX$558.88+3.50%
Upcoming Catalysts
Phase Distribution
252 lead-sponsored trials·32 active·195 completed
Phase 174
Phase 1/210
Phase 262
Phase 2/36
Phase 382
Phase 46
Not applicable12
(46 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Terminated

    Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

    Telaprevir, Ribavirin

    Hepatitis C

    Enrollment
    121
    Start
    Jan 2012
    Primary Completion
    May 2014
    Completion
    May 2014
    NCT01467492
  • Phase 4
    Terminated

    A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation

    LUM/IVA

    Cystic Fibrosis

    Enrollment
    24
    Start
    Jun 2016
    Primary Completion
    Aug 2017
    Completion
    Aug 2017
    NCT02823470
  • Phase 4
    Completed

    A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation

    LUM/IVA, Placebo

    Cystic Fibrosis

    Enrollment
    70
    Start
    Sep 2016
    Primary Completion
    Sep 2017
    Completion
    Oct 2017
    NCT02875366
  • Phase 4
    Completed

    A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries

    Suzetrigine

    Acute Pain

    Enrollment
    47
    Start
    Mar 2025
    Primary Completion
    Oct 2025
    Completion
    Nov 2025
    NCT06887959
  • Phase 4
    Completed

    A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries

    Suzetrigine

    Acute Pain

    Enrollment
    100
    Start
    Mar 2025
    Primary Completion
    Oct 2025
    Completion
    Nov 2025
    NCT06887972
  • Phase 4
    Active, not recruiting

    Evaluation of Pain Treatment After Total Knee Arthroplasty

    Suzetrigine, Placebo

    Pain

    Enrollment
    66
    Start
    Apr 2026
    Primary Completion
    Jan 2027est.
    Completion
    Jan 2027est.
    NCT07538570
  • Phase 3
    Completed

    A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

    Pegylated Interferon Alfa 2a, Telaprevir

    Hepatitis C

    Enrollment
    1,095
    Start
    Mar 2008
    Primary Completion
    May 2010
    Completion
    May 2010
    NCT00627926
  • Phase 3
    Completed

    A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

    telaprevir, ribavirin

    Hepatitis C

    Enrollment
    540
    Start
    Oct 2008
    Primary Completion
    Jun 2010
    Completion
    Jul 2010
    NCT00758043
  • Phase 3
    Completed

    Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation

    Ivacaftor, Placebo

    Cystic Fibrosis

    Enrollment
    167
    Start
    Jun 2009
    Primary Completion
    Jul 2010
    Completion
    Nov 2012
    NCT00909532
  • Phase 3
    Completed

    Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation

    Ivacaftor, Placebo

    Cystic Fibrosis

    Enrollment
    52
    Start
    Aug 2009
    Primary Completion
    Nov 2010
    Completion
    Apr 2011
    NCT00909727
  • Phase 3
    Completed

    Rollover Study of VX-770 in Cystic Fibrosis Subjects

    Ivacaftor

    Cystic Fibrosis

    Enrollment
    192
    Start
    Jul 2010
    Primary Completion
    May 2014
    Completion
    May 2014
    NCT01117012
  • Phase 3
    Terminated

    Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

    Telaprevir, Pegylated Interferon Alfa-2a

    Hepatitis C, Chronic

    Enrollment
    239
    Start
    Nov 2011
    Primary Completion
    Jan 2014
    Completion
    Jan 2014
    NCT01459913
  • Phase 3
    Terminated

    A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

    Telaprevir, Ribavirin

    Hepatitis C

    Enrollment
    185
    Start
    Dec 2011
    Primary Completion
    Feb 2014
    Completion
    Feb 2014
    NCT01467479
  • Phase 3
    Completed

    Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

    Ivacaftor, Placebo

    Cystic Fibrosis

    Enrollment
    70
    Start
    Jul 2012
    Primary Completion
    Oct 2013
    Completion
    Oct 2013
    NCT01614457
  • Phase 3
    Completed

    Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation

    Ivacaftor, Placebo

    Cystic Fibrosis

    Enrollment
    39
    Start
    Jul 2012
    Primary Completion
    Oct 2013
    Completion
    Oct 2013
    NCT01614470
  • Phase 3
    Completed

    Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

    Ivacaftor

    Cystic Fibrosis

    Enrollment
    35
    Start
    Jan 2013
    Primary Completion
    Mar 2014
    Completion
    Mar 2014
    NCT01705145
  • Phase 3
    Completed

    Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

    Ivacaftor

    Cystic Fibrosis

    Enrollment
    125
    Start
    Feb 2013
    Primary Completion
    Apr 2016
    Completion
    Apr 2016
    NCT01707290
  • Phase 3
    Completed

    A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

    Lumacaftor Plus Ivacaftor Combination, Ivacaftor

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    Enrollment
    559
    Start
    May 2013
    Primary Completion
    Apr 2014
    Completion
    Apr 2014
    NCT01807923
  • Phase 3
    Completed

    A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

    Placebo, Lumacaftor Plus Ivacaftor Combination

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    Enrollment
    563
    Start
    Apr 2013
    Primary Completion
    Apr 2014
    Completion
    Apr 2014
    NCT01807949
  • Phase 3
    Completed

    Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

    Lumacaftor, Ivacaftor

    Cystic Fibrosis

    Enrollment
    62
    Start
    Jul 2013
    Primary Completion
    Oct 2015
    Completion
    Oct 2015
    NCT01897233
  • Phase 3
    Completed

    A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

    Lumacaftor Plus Ivacaftor Combination, Ivacaftor

    Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

    Enrollment
    1,164
    Start
    Oct 2013
    Primary Completion
    Apr 2016
    Completion
    Apr 2016
    NCT01931839
  • Phase 3
    Completed

    Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

    Ivacaftor

    Cystic Fibrosis

    Enrollment
    33
    Start
    Dec 2013
    Primary Completion
    Dec 2015
    Completion
    Dec 2015
    NCT01946412
  • Phase 3
    Completed

    A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

    VX-661 Plus Ivacaftor Combination, Ivacaftor

    Cystic Fibrosis

    Enrollment
    510
    Start
    Jan 2015
    Primary Completion
    Jan 2017
    Completion
    Jan 2017
    NCT02347657
  • Phase 3
    Completed

    Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

    Lumacaftor, Ivacaftor

    Cystic Fibrosis, Advanced Lung Disease

    Enrollment
    46
    Start
    Mar 2015
    Primary Completion
    Oct 2016
    Completion
    Oct 2016
    NCT02390219
  • Phase 3
    Completed

    A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

    VX-661/Ivacaftor, Ivacaftor

    Cystic Fibrosis

    Enrollment
    248
    Start
    Mar 2015
    Primary Completion
    Feb 2017
    Completion
    Feb 2017
    NCT02392234

1-25 of 252

…
Search ClinicalTrials.gov for “Vertex Pharmaceuticals”